NCT00448968View on ClinicalTrials.gov

The Utility of Ischemia Modified Albumin (IMA) in Sepsis

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2007

Study Completion Date

September 30, 2007

Conditions
SepsisSevere SepsisSystemic Inflammatory Response SyndromeSepsis Syndrome
Trial Locations (3)

19104

University of Pennsylvania School of Medicine, Philadelphia

44195

Cleveland Clinc, Cleveland

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Inverness Medical Innovations

INDUSTRY

NCT00448968 - The Utility of Ischemia Modified Albumin (IMA) in Sepsis | Biotech Hunter | Biotech Hunter